Current and future therapy for hereditary angioedema
- 31 January 2005
- journal article
- review article
- Published by Elsevier in Clinical Immunology
- Vol. 114 (1), 10-16
- https://doi.org/10.1016/j.clim.2004.08.001
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Increased vascular permeability in C1 inhibitor–deficient mice mediated by the bradykinin type 2 receptorJournal of Clinical Investigation, 2002
- Hereditary AngioedemaArchives of Internal Medicine, 2001
- Plasma bradykinin in angio-oedemaThe Lancet, 1998
- C1 Inhibitor and Hereditary Angioneurotic EdemaAnnual Review of Immunology, 1988
- Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.Journal of Clinical Investigation, 1986
- Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykininJournal of Allergy and Clinical Immunology, 1983
- Prekallikrein Activation and High-Molecular-Weight Kininogen Consumption in Hereditary AngioedemaNew England Journal of Medicine, 1983
- Detection of active kallikrein in induced blister fluids of hereditary angioedema patients.The Journal of Experimental Medicine, 1980
- A biochemical abnormality in hereditary angioneurotic edemaThe American Journal of Medicine, 1963
- Hereditary angioneurotic edema: II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikreinJournal of Allergy, 1962